drugset / Trial / NCT07187895

Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis

NCT07187895

Phase 2 Terminated 17 enrolled Sinotau Pharmaceutical Group
NaSingle-groupOpen-labelDiagnostic

Summary

Compare the diagnostic certainty of MIBI SPECT myocardial perfusion imaging (MPI) and XTR004 PET MPI.

Timeline

Start
2024-12-19
Primary completion
2025-03-05
Completion
2025-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject XTR004 Diagnostic / imaging agent 74 mbq Intravenous
Subject XTR004 Diagnostic / imaging agent 92.5 mbq Intravenous
Subject XTR004 Diagnostic / imaging agent 222 mbq Intravenous
Subject XTR004 Diagnostic / imaging agent 277.5 mbq Intravenous
Background Adenosine Small molecule 140 ug/kg Intravenous